News

MPR4d
Iron Chaperone Granted Fast Track Status for Multiple System Atrophy
ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.
Medscape4d
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin
Background Multiple system atrophy (MSA ... was measured monthly. Quantitative brain imaging using 3T MRI was performed before and after treatment. Results Nine subjects were enrolled, and ...
Physician's Weekly1d
Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
To explore the role of brain and spinal cord MRI features in differentiating patients with suspected central nervous system (CNS) inflammatory diseases.Prospective data from 125 patients undergoing ...
TMCnet8d
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...
Morningstar8d
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Alterity’s previous interactions with the FDA indicated that the modified Unified Multiple ... System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved ...
TMCnet1d
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...